Clinical trial · Interventional
Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): insufficient recruitment
Summary
Brief summary (as posted)
Breast cancer is the first cancer in women and 60% of new cases occurring in women 50 to 74 years old. With about 50,000 new cases, it is the second cancer the most serious cancers. In the therapeutic strategy, hormone therapy takes pride of place by allowing a significant reduction in the recurrence rate. For the hormonotherapy be effective, patient compliance should be optimal during treatment. Different factors or barriers may lead to a lack of adherence, such as the occurrence of adverse effects, treatment fatigue, a difficult relationship with the health care team, beliefs about success or the need for treatment. In order to facilitate the compliance of hormonoherapy treatment by patients, it is important to include different health professionals such as pharmacists.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| interview | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pharmaceutical Interview
- description
- Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
- interventionNames
- Other: interview
Primary outcomes (1)
- measure
- Patient compliance
- timeFrame
- 18 months
- description
- data from electronic pillboxes
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Woman, over 18 years old. 2. With non-metastatic breast cancer. 3. Treated by hormone therapy, regardless of the molecule (cancer RH positive). 4. In primary prescription of hormone therapy. 5. First prescription by a medical oncologist, surgeon or radiation therapist from the CGFL. 6. Pharmacy of the patient located in the perimeter defined in the context of the study (Residents in the Burgundy region between a triangle delimited by the towns of Chatillon sur Seine, Dole and Chalon sur Saone. 7. Woman who received information about the study and gave her written consent. 8. Affiliation to a social security scheme. 9. Participant Agreement of the referent city pharmacy of the patient. Exclusion Criteria: 1. Metastatic patient. 2. Patient participating in another epidemiological or clinical study of adherence and / or hormone therapy. 3. Patient under guardianship, curatorship or safeguard of justice. 4. Patient with severe psychiatric disorders or who does not speak the French language 5. Refusal to participate in the study. 6. Refusal of participation of the referent city pharmacy of the patient.
References
Publications (0)
Data not yet available